Uncategorized

‘Are my medicines really necessary?’

New icon114x114

‘Are my medicines really necessary’ is one of the most frequent questions from our patient led clinical education sessions.

In this blog Steve Turner, Head of Medicines & Prescribing @MedicineGov,  reflects on the need to combine research and guidlelines with the patient’s actual experience, when deciding on medicines.

My experiences and learning

I was speaking about the use of medicines at a conference when I mentioned that medicines are ‘over prescribed’. Although nobody questioned and challenged me on this I was troubled by my use of this expression. By saying medicines are prescribed too frequently it seems to me this can be interpreted as a bad reflection on the prescribers.

As I mentally mulled this over (I’m not a quick thinker) I came to the conclusion that a beter expression may be ‘medicines are overused’. After all it’s us (the patients) who go to our Doctors, Pharmacists and Nurses and us who accept their prescriptions. Therefore if we agree that people can rely too heavily on medicines, and there’s wealth of evidence for this, then we need to sort this out together.

My social enterprise company’s Patent Led Clinical Education work came about because a large section of the population are prescribed multiple medicines, with potential for interactions and increased side-effects.

It’s widely accepted that 50% of the population don’t take their medicines as prescribed. Add to this the sometimes overlooked fact that people also use alternatives including over the counter medicines, herbal medicines , suplements, illicit drugs, self-medicate with alcohol, buy medicines over the internet, or borrow medicines from other people.


‘The human and financial costs of over use of medicines are immense. ‘


In our patient led clinical education sessions we have learned that many people don’t know what their individual medicines are for, and we see how many medicines are prescribed purely to counteract the side-effect of another medicine can pile up.


‘So far, nobody who has attended one of our sessions has expressed a wish to take more medicines, and those who did express a view all said that they didn’t want to take medicines if they didn’t have to.’


So what can we do together?

This blog aims to help us make sense of the vast amount of guidance available and describing why ‘trusted information’ is important in making decisions about medicines, and why this is only helpful if it it’s linked to the patient’s actual experience.

So much information, so many policies & guidance?

There’s an overwhelming amount of information and guidance on medicines, coming out on a daily basis. Even clinicians struggle to keep up and need help.

Two things are important in trying to make sense of this information overload.

  1. Making sure that the information you are looking at is from a ‘trusted’ source, (by this I mean ones that your prescriber is expected to use). see http://www.medsinfo.guru
  2. Linking this to patient experiences and support from others who have the same conditions.
  1. ‘Trusted’ information

The National Centre for Heath and Care Education [NICE] in England produces guidance, standards, indicators and evidence services covering health and social care. It’s not just about medicines. There’s a massive amount of trusted information on their web site, which covers:

  • Conditions and diseases
  • Health protection
  • Lifestyle and wellbeing
  • Population groups
  • Service delivery, organisation and staffing

To get a feel for this one place to start is the NICE Pathways, where you can browse the topics, pick one and have the information presented in a diagram, where you can click on the headings for more information.

In some areas has been a move away from producing guidelines on a single illness or condition to a more holistic person based approach. This better reflects the complexities of real life, where it would often be a luxury to have just one illness with no complicating factors. NICE guidance on medicines optimisation, multi-morbidity clinical assessment and management, and patient experience in adult NHS services are good examples.

In addition NICE produces a document on Key Therapeutic Topics as part of the NICE Medicines and Prescribing Programme. This document is reviewed and refreshed annually. Click here for the topic list.

Slide19

2. Patient experiences

Medicines (for adults) are tested and approved before that can be prescribed, and their safety is monitored, especially in the early stages, or if there are concerns (‘black traingle’ drugs). However drug trials are most often carried out on relatively small groups of people, usually from a limited range of ethnic groups, who who do not necessarily represent the population as a whole. For example, these ‘controlled trials’ usually exclude people with multiple illnesses, heavy drinkers or smokers, older people, and people with other illnesses such as addiction or mental ill health.

Controlled drugs trials are not carried out on children.

In addition the effect of medicines, including side-effects fall into two categories. Firstly, those that can be predicted (pharmaco-dynamic effects – that the effect of the drug on the body). Secondly, those that vary according to the bodily make up of the patient (called pharmaco-kinetic effects – the effect of the body on the drug).

It’s only when you combine the guidance with the specific circumstances of the patient, including the ethnicity and physical make up and lifestyle of the patient that a decision on a medicine can be made effectively. For this to work, the patient must be part of this decision, and be allowed to lead on their own care. Our work shows this:

Slide1

Testimonials on our patient led clinical education work.


tseUCsaH.jpg small

Uncategorized

Managing long term pain. A NICE Key Therapeutic Topic.

Medicines optimisation in long-term pain.

 

‘#jargonbuster ‘Medicines Optimisation’ means getting the medicines right for the individual. This may involve an alternative medicine, an alternative treatment or approach, and / or not taking medicines. The person’s experience, beliefs and what matters to them most should drive this decision, with clinicians providing guidance, advice and education on trusted sources of information, the evidence base and on safety’. (Steve Turner)

 

This is a brief summary relating to a topic in  the 2018 update of Medicines optimisation: key therapeutic topics

To access the pain management topic [KTT21] click here.

The section on medicines optimisation in long term pain contains a huge amount of information, including links to numerous other documents, on an areas critical to patient safety & wellbeing.

Key points:

Opioids

  • There is little evidence that opioids are helpful for long-term pain.
  • Patient safety incidents relating to the unsafe doses of opiates remain a major concern. People develop a ‘tolerance’ to opiate medicines, meaning that higher and higher doses may be needed to deliver the same effect. However this tolerance rapidly goes away when the opiates are stopped, so restarting at the old dose may be fatal.

 

This image is taken from: ‘Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.

FPM-5-a-day-graphic-2018

Click on the image to enlarge it.

Link: http://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware

 

‘A review of medicines-related safety incidents involving controlled drugs reported to the NRLS over 7 years found the risk of death with controlled drug incidents was significantly greater than with medication incidents generally (odds ratio 1.48, 95% CI 1.02 to 2.17). Incidents involving overdose of controlled drugs accounted for 89 (70%) of the 128 incidents reporting death or severe harm. Five controlled drugs (morphine, diamorphine, fentanyl, midazolam and oxycodone) were responsible for 113 (88%) of these 128 incidents.’

 

Non-opioid medicines in long-term pain

  • Patients can be prescribed gabapentin or pregabalin for certain types of pain. Both of these medicines can lead to dependence and may be misused or diverted.

#jargonbuster ‘diverted’ = passed on or sold one to someone else.

 

Finally, emotional influences are real:

  • When assessing pain with someone it’s vital that clinicians take all aspects of the person’s life into account, including lifestyle, nutrition, hydration, social and housing factors, safeguarding, sleep and rest, other illnesses, emotional influences and their mental health.

And take a full history of medicines being taken, or recently stopped, including over the counter medicines, internet bought medicines, borrowed medicines and illicit substances.


Overall key points to remember on pain management:

  • Adopt a  holistic patient-centered approach

  • Aim to prevent acute pain becoming chronic pain

  • There is little evidence that opioids are helpful for long-term pain


Related Guidance:

NICE Guidance NG5 Medicines Optimisation

NICE Guidance CG76 Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence

NICE Guidnace CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings

NICE Guidance NG59 Low back pain and sciatica in over 16s: assessment and management

Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain

NICE Guideline NG46 Controlled drugs safe use and management

NICE Guidance CG140 Palliative care for adults: strong opioids for pain relief


 

Steve is a nurse prescriber, Head of Medicines and Prescribing for @MedicineGov , Associate Lecturer at Plymouth University  and NICE Medicines and Prescribing Programme Associate.

mlkU-KY6.jpg large


 

Author: Steve Turner

First published 1/8/2017. Revised and updated 13/12/2018


 

Uncategorized

Managing medicines in care homes – four top tips –

Managing medicines in care homes – implementing Quality Standards.

This blog is designed to provide information for care homes and for those choosing a care home.

In a previous blog I looked at the implications of implementing the NICE Guideline on Managing Medicines in Care Homes.

As with all my posts this is a ‘rolling blog’. I welcome feedback and comments. I will take into account all feedback and use the blog to share new learning. If I’ve missed anything or I am wrong on something I will share the learning.

Some tips:

1. Care Homes must have a medicines policy that is regularly reviewed.

It’s worth considering how your policy links to staff training and how user friendly it is. Are procedures outlined clearly in the policy, do they link to competency assessments, and do you use checklists?

For example, we recently helped a care home produce a checklist of the key information needed when contacting a doctor. It is based on the SBAR (situation-background- assessment-recommendation) principle to help focus on the key information. This is proving popular as it saves time on the ‘phone, and the structured approach is popular with GPs. Staff commented that it has saved them hours of chasing, has improved responsiveness & their relationship with local services.

Here’s our method of working. It’s not rocket science and it works. I recommend this approach.

Slide2

2. People must have an accurate listing of their medicines on the day they transfer to the care home.

This is an area where care home staff are dependent on others. Hours can be spent trying to sort out problems. My advice here is for managers to ensure that discrepancies are always reported back to the source (in writing) and ask for feedback on how they are followed up. Additionally, it’s helpful to record your satisfaction with good quality and complete discharge information.

Our experience is that electronic systems can greatly improve quality of this information.

An NHS Patient Safety Alert highlights the importance of communication of discharge information.

3. People who live in care homes should have at least 1 multidisciplinary medication review per year.

There is considerable variation in practice around medicines reviews, with increasing help available from Clinical Commissioning Group Medicines Management Teams and Specialist Clinicians in most areas.

Although this is an area largely outside the control of care homes there are 3 things which can help.

  • Firstly, by consistently referring back any prescriptions which don’t have complete and unambiguous directions.
  • Secondly, by ensuring that there is an easily accessible record of what each medicine is being prescribed for, (regular medicines, one-off prescriptions and as required medicines). I am still amazed that this isn’t always the case.
  • And thirdly, whilst staff residents / relatives are not expected to be experts on medicines, access to basic information on each medicine, including on side-effects and interactions should be readily available.

4. Ensure you have safe systems for administering and recording medicines.

It is vital that you have a reliable and auditable system of MAR [medicine administration record] charts in place and that the process of administration of medicines to residents is safe.

Two main points spring to mind:

4.1. Monitored dose systmes [MDS] vs original pack dispensing [OPD].

There has been a recent move by some Pharmacies & local NHS teams to change residential homes from Monitored Dose Systems [MDS] (also called blister packs) back to Original Pack Dispensing [OPD] (sometimes referred to as ‘patient pack dispensing’). The reason for this is often given as to improve safety. It is sometimes implied that guidelines are driving this move back to original pack dispensing, even that OPD can help prevent polypharmacy & reduce medicines waste. All these statements are misleading.

Interestingly, the cost to the Pharmacy of putting the medicines in MDS blister packs is not mentioned in their promotions original pack dispensing [OPD].

I have not been able to find any evidence that original pack dispensing is safer than monitored dose systems. Additionally, the related NICE guidelines, quality standards and the CQC report ‘Medicines in Health and Social Care’ do not state this.

What’s important is that the home uses the safest system of delivering medicines to the residents, considering the patients’ wishes, the home’s skill mix, staff competencies, workload, and capacity. This is particularly important as staff tell me the original pack dispensing takes ‘twice as long’.

I am also aware of problems with OPD, for example: ‘Care home receives a box of meds. The medication is checked in and the resident has 2 MAR entries for same drug. Diligent staff member (calls the system provider and) prevents patient harm.In this example the boxed medicine had the wrong start date, which led to duplication on the MAR chart. In a blister the dispenser would have noticed the start date error on one item and made the data entry correction prior to the box medicine reaching the patient’s bedside.

My advice on the subject of MDS vs OPD is that if you are being lobbied to change to original pack dispensing, here are some key questions to consider:

A. Bearing in mind that OPD could take twice as long, what are the advantages of moving to this? Can you be sure, for example, that unsafe practices such as ‘potting up’ will not creep into use? Will it improve patient safety & compliance with NICE Guidelines and quality standards?

B. Ask for evidence of the benefits of OPD as opposed to MDS.

C. Ask for evidence to back up the claim that OPD will help reduce polypharmacy? (In my view this is a bizarre claim).

D. Ask for evidence to back up the claim that OPD will reduce medicines waste.

E. Ask the residents or their families, or (if there’s a Lasting Power of Attorney [LPA] or Court of Protection order in place), ask the Attorneys or Deputys.

F. Ask the staff.

G. Ask the prescribers.

I’m interested in feedback on this. I am a nurse by trade and used to be a proponent of OPD in all circumstances. Since working in social care and with residential homes I’ve re-visited this view.

Care home residents need well designed systems. Unless the patient can manage their medicines themselves (always the first consideration), a good MDS system is often a safer way to administer medicines.

4.2 . The benefits of using electronic MAR charts.

blister pack 3

These fall into three categories.

  1. Improved legibility.
  2. Improved access (e.g., if the charts are accessed and updated on a computer or portable device there is less risk of losing, damaging, or mislaying them).
  3. eMAR chart systems that obtain the data taken directly from the Community Pharmacy system eliminate the need for transcribing, which is a high-risk area.

In addition to the three benefits mentioned, carefully planned, and implemented eMAR systems contribute to a decrease in medicines errors, reduced administrative costs and improved quality of care.

Click here to read more about eMAR systems.

tseUCsaH.jpg small
Steve Turner

Last updated: 06.10.2024


Useful links:

NICE Guideline Managing Medicines in Care Homes

NICE Quality Standard Managing Medicines in Care Homes

CQC Managing Medicines in Health and Adult Social Care


blister-pack-3.jpg
Accountability, clinical education, Clinical Governance, health, healthcare, medicines, nhs, patients

Using technology in care homes to improve safety- Electronic medicines administration systems – eMAR –

Introduction

Medicines errors in care homes are unacceptably high. A key study found that residents taking seven or more medicines had a 79% chance of being victim of a medicines error (Alldred et all 2009). This led to several follow-up studies and actions to improve medicines management in care homes, including a move to implement electronic medicines administration [eMAR] systems. A recent study explored medication-related incidents and their causes in UK care homes. This review emphasised the need for improved medication management processes to reduce errors and enhance patient safety (Irons et al 2022).

Slide1

Best practice in medicines record keeping

The management of medicines in nursing and residential homes is part of a highly complex pathway.  It involves multiple staff groups and organisations.

These include the G.P.; all who prescribe medicines and treatments; Care Staff of all grades; Support Workers; Consultants; Specialist Practitioners; and Pharmacists.

Benefits of electronic MAR charts

The benefits of implementing electronic MAR charts fall into three categories.

  1. Improved legibility.
  2. Improved access (e.g., if the charts are accessed and updated on a computer or portable device there is less risk of losing, damaging, or mislaying them).
  3. eMAR chart systems that obtain the data taken directly from the Community Pharmacy system eliminate the need for transcribing.

Systemitic reviews indicate that carefully planned and implemented eMAR systems contribute to a decrease in medicines errors, reduced administrative costs and improved quality of care (Gates et al 2021).

Challenges of implementing electronic MAR charts

There are three ‘bottom line’ challenges to manage when transitioning to electronic MAR charts.

1. Assessing potential eMAR systems. This is critical, as poorly designed systems will not deliver benefits, and eventually fail. The system must be easy to use and free of unnecessary jargon, using only approved acronyms or mnemonics. Electronic systems also offer the opportunity to introduce features which enhance safety, some of which, such as time ordered charts, are difficult to include in a paper-based syste

Here’s a some key features to look for:

  • Photo identification
  • Time ordered charts
  • Body maps
  • Drug images
  • Start and finish dates
  • Insulin charts
  • Warfarin charts
  • As required – prn- charts
  • Does the system record the reason prn medicines were given?
  • Medication history
  • Medication profiles
  • How the system records allergies and sensitivities
  • What alerts and warning messages are included?
  • How the system copes with medicines dispensed directly from hospitals
  • How does the system cater with titration of medicines and variable doses
  • How does the system cater with weekly medicines (e.g. alendronic acid)?
  • Use of monitoring information (e.g. INR for warfarin administration, lithium level recording, BMI, B/P, pulse etc.)
  • That the system uses up to date approved terminology
  • Does the system records medicines not given or partially administered, with a reason?
  • How the system can be used to order and control stocks of medicines
  • How easy is it to produce reports from the system?

2. Data Security and Protection. It is vital that the system handles patient consent; patient confidentiality, system access; ownership of patient identifiable data; storage and transfer of data in a way which is compliant with the laws and regulations of your part of the U.K.

All organisations and systems that access to NHS patient data must successfully complete the NHS data security and protection toolkit [DSPT]. This toolkit provides assurance that the system suppliers are handling data safely and that personal information is handled correctly. You can search the supplier’s NHS DSPT registration here: https://www.dsptoolkit.nhs.uk/OrganisationSearch

3. Process Reviews. It is important to look at your current processes and how the new system will work. For example, there have been problems where urgent acute prescriptions were supplied by a different pharmacy from the pharmacy linked to the home’s eMAR system. The eMAR system must be able to cope with all aspects of prescribing from multiple sources and prevent information having to be duplicated.


Training and support requirements

Quality training and support, both during the implementation and on an ongoing basis, underpin all successful healthcare I.T systems. There are four areas which are sometimes overlooked that deserve special mention:

1.  Many of the users of eMAR systems will be Healthcare Assistants or other non-registered skilled staff. As a result, it will be important that the training they receive reinforces their duty to keep accurate records, that they know where to go for help and advice and their role and responsibilities are made clear.

2. A substantial number of staff may speak English as a second language. Therefore, it is important that eMAR systems do not use any unnecessary jargon, and that any help text is in plain language.

3. Appropriate knowledge of Data Protection (GDPR) and Information Governance rules and regulations is essential and should be built into any training programmes.

Overall, consideration needs to be given to the nature and content of the training needed to implement the system, including how this is linked to the policies and procedures and overall governance of the home.

Good suppliers will be able to give advice and support on this.


Conclusion

Record keeping in medicines management is a critical safety area for care homes. The current high level of medicines errors is in care homes affects half a million people in England.

The prospect of implementing electronic systems for recording medicines administration holds great potential but is not itself without risk. It needs to be approached carefully in the light of the complex arrangements and multiple organisations involved in prescribing, supplying, administering, dispensing and monitoring medicines for your residents.

Given the considerations over choice and implementation of systems, eMAR can overcome problems of legibility, transcribing, and access to records and information in a way which is not possible with paper systems.

In years to come it is likely that, just as most G.P.’s would not want to return to paper systems, care homes will come to see electronic systems in the same way. The main beneficiary of this will be the residents in terms of improved safety.



References:

  • Alldred P, Barber N, Buckle P et al (2009) Care home use of medicines study (CHUMS): Medication errors in nursing and residential care homes – prevalence, consequences, causes and solutions. Report to the Patient Safety Research Portfolio. Department of Health, London.
  • Peter J Gates, Rae-Anne Hardie, Magdalena Z Raban, Ling Li, Johanna I Westbrook, How effective are electronic medication systems in reducing medication error rates and associated harm among hospital inpatients? A systematic review and meta-analysis, Journal of the American Medical Informatics Association, Volume 28, Issue 1, January 2021, Pages 167–176, https://doi.org/10.1093/jamia/ocaa230
  • Irons, M. W., Auta, A., Portlock, J. C., & Manfrin, A. (2022). Medication errors and processes to reduce them in care homes in the United Kingdom: a scoping review. Home Health Care Services Quarterly41(2), 91–123. https://doi.org/10.1080/01621424.2021.2007196



Author: Steve Turner RGN, RMN, Ba (Hons), PG Dip Ed – an experienced nurse educator, who has worked in strategic consultancy and on change projects across healthcare in the UK.

Blog last Updated: 05.07.2025